Physician profile
Norman M Gordon
NPI 1467481648
$206,164.27
in general payments reported to CMS, 2019-2025
72 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $49K · 2021: $49K · 2022: $23K · 2023: $8,816 · 2024: $7,070 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Consulting Fee: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,300 · Travel and Lodging: $868 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,811.63 |
| Consulting Fee | $11,535.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,300.00 |
| Travel and Lodging | $868.17 |
| Education | $210.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42,542.84 | 2019-2025 | Uplizna, Aimovig |
| Teva Pharmaceuticals USA, INC. | $35,495.98 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $20,723.11 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $12,586.89 | 2020-2021 | |
| Emd Serono, INC. | $11,231.58 | 2019-2025 | Mavenclad, Mavenclad |
| Allergan, INC. | $10,662.30 | 2019-2022 | |
| Neurelis, INC. | $10,555.82 | 2020-2022 | |
| Pfizer INC. | $9,498.70 | 2021-2025 | |
| Acorda Therapeutics, INC | $8,853.73 | 2019-2023 | Inbrija |
| Lundbeck LLC | $5,778.57 | 2019-2024 | Vyepti, Rexulti |
| Eisai INC. | $5,148.10 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $4,895.86 | 2022 | |
| Amneal Pharmaceuticals LLC | $3,708.11 | 2019-2025 | Lyvispah, Rytary, Ongentys |
| Mdd US Operations, LLC | $3,136.57 | 2019-2025 | Gocovri, Apokyn, Gocovri |
| Sunovion Pharmaceuticals INC. | $1,769.95 | 2019-2022 |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,769.68 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Novartis Pharmaceuticals Corporation | $1,764.10 | 2019-2025 | |
| Sk Life Science, INC. | $1,612.24 | 2020-2025 | |
| Acadia Pharmaceuticals INC | $1,387.15 | 2019-2025 | Nuplazid, Daybue |
| Banner Life Sciences, LLC | $1,135.17 | 2021-2022 | |
| Ucb, INC. | $1,058.70 | 2019-2025 | Nayzilam, Fintepla, Briviact |
| Lilly USA, LLC | $927.88 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Kyowa Kirin, INC. | $739.28 | 2019-2024 | Nourianz |
| Genzyme Corporation | $692.95 | 2019-2025 | |
| Celgene Corporation | $682.79 | 2021-2025 | Zeposia |
| Neurocrine Biosciences, INC. | $647.46 | 2019-2025 | Ingrezza, Ongentys |
| Catalyst Pharmaceuticals, INC. | $622.81 | 2019-2025 | Fycompa, Firdapse |
| Sumitomo Pharma America, INC. | $540.56 | 2023-2024 | Aptiom |
| Avanir Pharmaceuticals, INC. | $511.83 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $466.23 | 2019-2025 | Onpattro, Givlaari |
| Jazz Pharmaceuticals INC. | $428.02 | 2019-2025 | |
| Genentech USA, INC. | $362.64 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Livanova USA, INC. | $328.04 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Adamas Pharmaceuticals, INC. | $297.30 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $253.39 | 2023-2025 | Rexulti, Nuedexta |
| Tg Therapeutics, INC. | $240.89 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $214.41 | 2022-2023 | Ponvory |
| Csl Behring | $188.13 | 2019-2025 | Hizentra |
| Upsher-Smith Laboratories LLC | $186.47 | 2019-2023 | |
| Medtronic, INC. | $180.85 | 2023 | Percept Pc Brainsense |
| Supernus Pharmaceuticals, INC. | $174.08 | 2021-2025 | Qelbree |
| Insightec,INC | $149.65 | 2022-2024 | Exablate |
| E.R. Squibb & Sons, L.L.C. | $146.51 | 2020 | |
| Assertio Therapeutics, INC. | $138.06 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $130.16 | 2023 | Trudhesa |
| Argenx US, INC. | $124.67 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Vanda Pharmaceuticals INC. | $122.38 | 2024-2025 | Ponvory |
| Alexion Pharmaceuticals, INC. | $115.17 | 2019-2023 | Ultomiris, Soliris |
| Tanabe Pharma America, INC. | $114.45 | 2021-2025 | Radicava |
| Sanofi-Aventis U.S. LLC | $111.12 | 2021 | |
| Octapharma USA, INC. | $109.96 | 2024-2025 | Panzyga |
| Ani Pharmaceuticals, INC. | $76.86 | 2023-2025 | Purified Cortrophin Gel |
| Almatica Pharma LLC | $76.22 | 2021 | |
| Horizon Therapeutics Plc | $75.43 | 2022-2023 | Uplizna |
| Organon LLC | $71.43 | 2025 | Vtama |
| Avion Pharmaceuticals | $68.51 | 2022-2023 | Dhivy |
| Xeris Pharmaceuticals, INC. | $61.00 | 2023-2024 | Keveyis, Gvoke Hypopen |
| Harmony Biosciences LLC | $60.64 | 2025 | |
| Ge Healthcare | $58.90 | 2019-2021 | |
| Inspire Medical Systems, INC. | $46.53 | 2024 | Inspire |
| Cycle Pharmaceuticals INC | $40.71 | 2024-2025 | Bafiertam, Tascenso Odt, Ormalvi |
| Medtronic USA, INC. | $35.35 | 2019 | |
| Currax Pharmaceuticals LLC | $32.84 | 2020 | |
| Life Molecular Imaging Ltd | $30.36 | 2024 | Neuraceq |
| Axsome Therapeutics, INC. | $30.00 | 2023 | Sunosi |
| Aquestive Therapeutics, INC. | $21.57 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $21.54 | 2022 | |
| Merz Pharmaceuticals, LLC | $20.68 | 2025 | Inbrija, Xeomin |
| Kedrion Biopharma, INC. | $19.81 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Koate |
| Arbor Pharmaceuticals, INC. | $17.63 | 2019 | |
| Neuropace, INC. | $17.58 | 2019 | |
| Invivyd INC | $17.39 | 2025 | Pemgarda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,500.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.